Long QT syndrome (LQTS) is a cardiovascular disorder characterized by an abnormality in cardiac repolarization leading to a prolonged QT interval and T-wave irregularities on the surface electrocardiogram (ECG). It is commonly associated with syncope, seizures, susceptibility to torsades de pointes, and risk for sudden death. LQTS is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. The availability of therapy for this lethal disease emphasizes the importance of early and accurate diagnosis. Additionally, understanding of the molecular mechanisms underlying LQTS could help to optimize genotype-specific treatments to prevent deaths in LQTS patients.

In this review, we briefly summarize current knowledge regarding molecular underpinning of LQTS, in particular focusing on LQT1, LQT2, and LQT3, and discuss novel strategies to study ion channel dysfunction and drug-specific therapies in LQT1, LQT2, and LQT3 syndromes.

**KEYWORDS** Genetic variants; Induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM); Long QT syndrome; Potassium channel; Precision medicine; Sodium channel

(Bench to bedside – Long QT syndrome – Bench to bedside)

There are 17 subtypes of congenital LQTS, each associated with a different gene (Table 1). The most frequent LQTS subtypes are type 1 (LQT1), type 2 (LQT2), and type 3 (LQT3). LQT1 is associated with mutations in KCNQ1 (IKs potassium channel [Kv7.1]), LQT2 is caused by mutations in KCNH2 (IKr potassium channel [Kv11.1]), and mutations in SCN5A (INa sodium channel [NaV1.5]) are linked to LQT3. These 3 genes combined account for approximately 65% of all LQTS and approximately 80% of genotype-positive LQTS cases (Table 2). Less frequently, LQTS-associated mutations exist in many other genes (KCNJ2, KCNJ5, CACNA1C, KCNQ1, KCNE2, AKAP9, ANK2, SCNA4B, SNTA1, CALM1-3, CAV3, and TRDN) encoding for ion channels, regulatory channel subunits, and signaling or adaptor-associated proteins.

**Molecular underpinning of LQTS**

The normal electrophysiological behavior of the heart is determined by ordered propagation of excitatory stimuli that result in rapid depolarization and slow repolarization, thereby generating cardiac action potentials (APs) in individual myocytes. Abnormalities of impulse generation, propagation, or the duration and configuration of individual cardiac AP waveform are the basis of disorders of cardiac rhythm and contractile dysfunction.
Long QT syndrome (LQTS) is a cardiovascular disorder characterized by an abnormality in cardiac repolarization leading to a prolonged QT interval. It is commonly associated with syncope, seizures, susceptibility to torsades de pointes and risk for sudden death.

At this time there are 17 subtypes of congenital LQTS, each associated with a different gene. The most frequent LQTS subtypes are LQT1, associated with mutations in KCNQ1; LQT2, caused by mutations in KCNH2; and LQT3, associated with mutations in SCN5A.

Hundreds of LQTS mutations are found in KCNQ1, KCNH2, and SCN5A genes. Yet even within 1 gene, the mutations present with different mechanisms and different severity and, even more importantly, variability is also seen for the same mutation among different patients.

Early diagnosis is important to identify LQTS patients at lower vs higher risk of cardiac events, to determine the appropriate therapy, and to identify LQTS patients displaying incomplete penetrance with different clinical phenotypes.

In general, beta-blocker therapy is the drug treatment of choice for LQTS patients.

The use of human induced pluripotent stem cell–derived cardiomyocytes, next-generation sequencing, high-throughput patch-clamping, and deep mutation scanning are all relatively new approaches that have been applied to the study of LQTS and we are starting to see the benefits by translating our findings from bench to bedside.

KEY FINDINGS

- Long QT syndrome (LQTS) is a cardiovascular disorder characterized by an abnormality in cardiac repolarization leading to a prolonged QT interval. It is commonly associated with syncope, seizures, susceptibility to torsades de pointes and risk for sudden death.
- At this time there are 17 subtypes of congenital LQTS, each associated with a different gene. The most frequent LQTS subtypes are LQT1, associated with mutations in KCNQ1; LQT2, caused by mutations in KCNH2; and LQT3, associated with mutations in SCN5A.
- Hundreds of LQTS mutations are found in KCNQ1, KCNH2, and SCN5A genes. Yet even within 1 gene, the mutations present with different mechanisms and different severity and, even more importantly, variability is also seen for the same mutation among different patients.
- Early diagnosis is important to identify LQTS patients at lower vs higher risk of cardiac events, to determine the appropriate therapy, and to identify LQTS patients displaying incomplete penetrance with different clinical phenotypes.
- In general, beta-blocker therapy is the drug treatment of choice for LQTS patients.
- The use of human induced pluripotent stem cell–derived cardiomyocytes, next-generation sequencing, high-throughput patch-clamping, and deep mutation scanning are all relatively new approaches that have been applied to the study of LQTS and we are starting to see the benefits by translating our findings from bench to bedside.

On the surface ECG, the QT interval reflects the duration of the ventricular AP generated by various cardiac ion currents, including sodium, calcium, and potassium currents. The QT prolongation is the hallmark of LQTS, and it may rise to early afterdepolarizations and transmural dispersion of refractoriness generating an electrical substrate that can give rise to torsades de pointes and risk for sudden death.

LQT1, IKs loss of function

IKs, KCNQ1/KCNE1 channel

KCNQ1 is the pore-forming α-subunit of the slowly activated delayed-rectifier K+ current (Kv7.1). In cardiac cells, KCNQ1 co-assembles with the β-subunit KCNE1 (MinK) to form IKs. IKs is the outward K+ current generated by KCNQ1/KCNE1 complex and is one of the repolarizing K+ currents that contribute to the termination of the cardiac AP. IKs primarily contributes to AP repolarization during β-adrenergic stimulation, when its current amplitude is increased and rate of activation accelerated.

Like other voltage-gated ion channels, KCNQ1 shares a common core structure of 4 identical α-subunits, each containing 6 membrane-spanning segments with a voltage-sensing domain (S1–S4) and a pore loop domain (S5–S6) that contributes to the ion selectivity filter in the homotramers to create the KCNQ1 channel. Additionally, KCNQ1 subunits possess a large COOH terminus, which is important for channel gating, assembly, and trafficking (Figure 2A).

Interacting ion channel subunits KCNQ1 and KCNE1 have received intense investigation owing to their critical importance in human cardiovascular health. In addition to KCNE1, the other 4 members of the KCNE family (KCNE2–5) are capable of associating with KCNQ1, to also regulate channel behavior and to confer specific pharmacological features to the IKs current. Interactions between the transmembrane domains of the α- and β-subunits determine the activation kinetics of IKs. Additionally, a physical and functional interaction between COOH termini of the proteins has also been identified that impacts deactivation rate and voltage dependence of activation, enhancing phosphatidylinositol-4,5-bisphosphate sensitivity. This proximal COOH termini region of functional interaction between KCNQ1/KCNE1 complexes is between the KCNQ1 residues 352–374 and KCNE1 residues 70–81. Additionally, there is strong evidence that deleterious mutations in either gene KCNQ1 or KCNE1 are associated with loss of IKs function and result in LQT1 and LQT5, respectively.

Ca2+- and calmodulin modulation of KCNQ1/KCNE1 channel

KCNQ1/KCNE1 complex interaction is a dynamic process; it has been shown that under basal conditions, KCNE1 in adult ventricular myocytes maintains a stable presence on the surface, whereas KCNQ1 is dynamic on its localization. KCNQ1 is largely in intracellular reservoirs but can traffic to the cell surface and boost the IKs amplitude in response to stress in a Ca2+- and calmodulin (CaM)-dependent manner. CaM acts as an additional essential auxiliary subunit of the KCNQ1/KCNE1 complex, with CaM binding to the proximal COOH termini of the KCNQ1 channel. CaM binding to KCNQ1 is essential for correct channel folding and assembly and for conferring Ca2+-sensitive IKs stimulation, which increases the cardiac repolarization reserve.

Mutations associated with LQT syndrome located near the IQ motif mediate Ca2+-free CaM binding to KCNQ1 at the COOH termini, which impairs CaM binding to KCNQ1, alters channel assembly, and stabilizes inactivation, which results in a decrease in current density.
Table 1  Subtypes of congenital long QT syndrome and their associated genes, proteins and effects on cardiac currents

| LQTS type | Gene | Protein | Function | Mechanism | Reference |
|-----------|------|---------|----------|-----------|-----------|
| LQT1      | KCNQ1| Kv7.1   | α-subunit I\(_Ks\) | Loss of function | Wang et al 1996 |
| LQT2      | KCNH2| Kv11.1  | α-subunit I\(_Kr\) | Loss of function | Sanguinetti et al 1995; Curran et al 1995 |
| LQT3      | SCN5A| Na\(_v\)1.5 | α-subunit I\(_Na\) | Gain of function | Wang et al 1995 |
| LQT4      | ANK2 | Ankyrin B | Adaptor | Loss of function | Mohler et al 2003; Schott et al 1995; Splawski et al 1997; Schulze-Bahr et al 1997 |
| LQT5      | KCNE1| minK    | β-subunit I\(_Ks\) | Loss of function | Abbott et al 1999 |
| LQT6      | KCNE2| MIRP1   | β-subunit I\(_Kr\) | Loss of function | Plaster et al 2001 |
| LQT7       | KCNJ2 | Kir2.1 | α-subunit I\(_K1\) | Loss of function | Splawski et al 2004 |
| LQT8       | CACNA1C | Cα1.2 | α-subunit I\(_Ca\) | Gain of function | Vatta et al 2006 |
| LQT9       | CAV3 | Caveolin | Adaptor | Loss of function | Medeiros-Domingo et al 2007 |
| LQT10      | SCN4B| Na\(_v\)β4 | β-subunit I\(_Na\) | Loss of function | Chen et al 2007; Bottiglieri et al 2019 |
| LQT11      | AKAP9 | Yotiao, (A- anchor protein 9) | Adaptor | Loss of function | Ueda et al 2008 |
| LQT12      | SNTA1| α1-syntrophin | scaffolding | Loss of function | Wang et al 1996 |
| LQT13      | KCNJ5| Kir3.4  | α-subunit I\(_K_Ach\) | Loss of function | Yang et al 2010 |
| LQT14      | CALM1| Calmodulin 1 | Signaling protein | Dysfunctional Ca\(^{2+}\) Signaling | Splawski et al 2016; Bozcek et al 2016 |
| LQT15      | CALM2| Calmodulin 2 | Signaling protein | Dysfunctional Ca\(^{2+}\) Signaling | Splawski et al 2016; Bozcek et al 2016 |
| LQT16      | CALM3| Calmodulin 3 | Signaling protein | Dysfunctional Ca\(^{2+}\) Signaling | Splawski et al 2016; Bozcek et al 2016 |
| LQT17      | TRDN | Triadin | Ca\(^{2+}\) homeostasis regulation | Loss of function | Vatta et al 2006 |

LQTS = Long QT syndrome.
Adapted from reference Bohnen et al 2017 and Adler et al 2020.

**PIP\(_2\) regulation of KCNQ1/KCNE1 channel**

The channel activity of KCNQ1 is also regulated by signaling lipid PIP\(_2\). PIP\(_2\) functions as a co-factor of KCNQ1 homotrimers as well as its complexes with different KCNEs. PIP\(_2\) is required to stabilize the KCNQ1/KCNE1 channel open state, leading to an increased current amplitude, slowed deactivation kinetics, and a shift in the activation curve toward negative potentials.\(^{43}\) In addition, the auxiliary β-subunit KCNE1 increases PIP\(_2\) sensitivity over channels formed by the pore-forming α-subunit KCNQ1 alone.\(^{35,52-54}\) Several LQT-associated mutations reduce PIP\(_2\) affinity for KCNQ1,\(^{49}\) and there is evidence that KCNE1 can alter the function of I\(_Ks\) by modulating the interaction between PIP\(_2\) and the heteromeric ion channel complex. Mutations of the putative PIP\(_2\) interaction site in KCNE1 (R67C, R67H, K70M, and K70N) have also been identified in LQT patients as disease-associated mutations.\(^{50}\)

**β-adrenergic receptor modulation of KCNQ1/KCNE1 channel**

The A-kinase anchoring protein 9 (AKAP-9) is another critical protein that modulates adrenergic response of the KCNQ1/KCNE1 complex.\(^{50}\) AKAP-9, also known as yotiao protein, is a scaffolding protein that dynamically recruits signaling molecules and presents them to downstream targets to achieve efficient spatial and temporal control of their phosphorylation state.\(^{51}\) In the heart, sympathetic nervous system (SNS) regulation of the action potential duration (APD) mediated by β-adrenergic receptor requires assembly of AKAP-9 with I\(_Ks\) α subunit. AKAP-9 directly binds to KCNQ1 by a leucine zipper motif localized in its COOH termini and recruits the signaling molecules adenosine 3’, 5’-monophosphate (cAMP)-dependent protein kinase, phosphatase 1, phosphodiesterase, and adenylyl cyclase 9 to KCNQ1 through its binding.\(^{50,52-54}\) Mutations that disrupt I\(_Ks\)-AKAP-9 interaction result in reduced protein kinase-dependent phosphorylation of I\(_Ks\) subunit KCNQ1 and inhibition of the SNS stimulation of I\(_Ks\), which can lead to LQTS. Different AKAP-9 mutations have been associated with LQTS\(^{55,56}\) classified as LQT11. In addition, AKAP-9 has been identified as a genetic modifier of LQT1 syndrome contributing to phenotypic variability in patients with the same primary-causing mutation.\(^{20}\)

**Clinical aspects and arrhythmic triggers**

Under normal physiological conditions, sympathetic activation promotes I\(_Ks\), which shortens ventricular repolarization against the activation of L-type Ca\(^{2+}\) channel and thereby protects against Ca\(^{2+}\)-related arrhythmogenicity. When I\(_Ks\) is defective owing to KCNQ1/KCNE1 channel mutations, the ventricular repolarization or QT intervals fails to shorten appropriately, thus creating a highly arrhythmogenic condition.\(^{57}\)

In patients with LQT1 syndrome, cardiac events are more frequently triggered by adrenergic stimuli (eg,
physical and emotional stress). Studies indicated that LQT1 patients experience the majority of their events during exercise (55%), with arousal (14%), with sleep/rest (21%), and with other triggers (10%).

Additionally, analysis showed that male LQT1 patients are younger than female at first event, and male patients, 13 years old had a 2.8-fold increase in the risk for exercise-trigger events, whereas female patients showed a 3.5-fold increase in the risk for sleep/rest nonarousal events. Moreover, during adulthood, LQT1 female patients have a significantly higher risk of cardiac events compared to respective male patients. It has been suggested that patients with LQT1 may need greater attention and advanced treatment early during their lifetime since they exhibited an increased probability of cardiac events during the first 20 years of life. Together, these reports stress the importance of age-related therapy for genotype LQTS patients.

Several studies have focused on determining factors associated with the occurrence of cardiac events in LQTS patients. Principally, clinical and genetic findings associated swimming and water activities with precipitation of cardiac events in LQT1 patients. Recently, an in vivo study aimed to compare LQTS responses to arrhythmia triggers reported that in response to simulated diving, a slower heart rate was observed in LQT1 patients. The authors of the study mentioned that although bradycardia is a well-established risk factor for arrhythmias in LQTS patients, further studies are needed to fully understand the association with swimming-associated events.

Furthermore, genotype-phenotype studies in LQT1 syndrome indicated that LQT1 patients with mutations located in the transmembrane portion of the ion channel are at the highest risk of congenital LQTS-related cardiac events and have greater sensitivity to sympathetic stimulation compared with patients with COOH terminal mutations. In addition, the degree of ion channel dysfunction caused by the mutations is an important independent risk factor influencing the clinical course of this disorder.

Several studies were aimed at determining the relation between arrhythmic risk factors and mutation location; yet the factors that could determine the genotype-phenotype severity in LQT1 syndrome patients remain unclear. However, further examination of this correlation will be important to offer an efficient management and treatment of the patients with LQT1 syndrome. Great advances in high-throughput screening of mutations will certainly greatly help toward this goal, as described later on in this review.

### Table 2 Distinguishing features of long QT syndrome for the most common genetic mutations

| Genotype | LQT1 | LQT2 | LQT3 | Reference |
|----------|------|------|------|-----------|
| Genetics | KCNQ1 | KCNH2 | SCN5A | Wang et al 1996; Sanguinetti et al 1995; Curran et al 1995; Wang et al 1995 |
| Frequency,% | 42-49% | 39-45% | 8-10% | Splawski et al 2000; Napolitano et al 2005; Wang et al 1996; Sanguinetti et al 1995; Curran et al 1995; Wang et al 1995 |
| Function | Loss-of function | Loss-of function | Gain-of-function | Schwartz et al 2001; Sakaguchi et al 2008; Goldenberg et al 2012; Kim et al 2010 |
| Ion current affected | ↓ I_Ks | ↓ I_Kr | ↑ I_Na | Wang et al 1996; Sanguinetti et al 1995; Curran et al 1995; Wang et al 1995 |
| Incidence of cardiac events frequently triggered by,% | Exercise, (swimming and water activities) 55% | Arousal-triggers, (sudden loud noise), 44% | Rest, 29% | Schwartz et al 2001; Sakaguchi et al 2008; Goldenberg et al 2012 |
| Likelihood of dying during a cardiac event,% | 4% | 4% | 20% | Zareba et al 1998; Wilde et al 2016 |
| Response to β-blockade | + + + | + + | Controversial | Priori et al 2013; Priori et al 2016; Ahn et al 2017; Mazzanti et al 2018; MacIntyre et al 2020; Chorin et al 2018; Chorin et al 2016; Blisch et al 2019; Chorin et al 2016; Moss et al 2008 |
| Response to sodium channel blockers | + + | + + | | |

+, low likelihood; + +, moderate likelihood; + + +, high likelihood.
LQT2, IKr loss of function

IKr, KCNH2/KCNE2 channel

KCNH2 is also known as the human ether-a-go-go-related gene (hERG). Two channel α subunits encoded by KCNH2 (hERG 1a and 1b) are expressed in cardiac tissues and both isoforms encode the voltage-gated Kv11.1 channel α subunit, which underlies the rapid component of the delayed inward-rectifying K+ current (IKr). IKr is characterized by slow activation and deactivation kinetics, coupled to rapid inactivation and recovery from inactivation, which are partially responsible in determining the prolonged plateau phase typical of the ventricular AP. The most distinct and physiologically significant gating characteristics of hERG channel are its rapid inactivation and slow deactivation.

The presence of rapid inactivation means that with the cell membrane depolarization, the channel opens but it very quickly enters the inactivated state (nonconducting), passing very little current in the outward direction. As the AP repolarization begins, hERG channels recover from inactivation, so the channel retraces its conformational steps and passes through the open state on the way back to its closed configuration, which occurs when the membrane returns to its normal resting potential near -80 mV.

When expressed heterologously, hERG1a homomeric and 1a/1b heteromeric channels yield robust currents. In contrast, homomeric hERG 1b channels produce undetectable or very small currents. Furthermore, hERG1a/1b channel subunits directly interact and preferentially form heteromeric channels. The hERG 1a/1b channels differ in their primary structure and functional

Figure 1 From the electrocardiogram (ECG) to cellular ion currents. Voltage-activated Na+ and K+ currents define the ventricular action potential and the QT interval of the ECG. A: Simulated ECG trace in normal conditions (black trace) and LQTS (red trace). The rapid upstroke of the ventricular action potential gives rise to the QRS complex. The duration of the QT interval is determined by the time of the ventricular repolarization. B: Simulated ventricular action potential in physiological situation (black trace), the rapidly activating and inactivating peak INaL drives membrane depolarization; a very small sustanied or late INaL is present. Two K+ currents, IKs and IKr, contribute mostly to the plateau phase and repolarization phase of the action potential, which restores the membrane resting potential. Simulated functional effect of loss of function of either IKs or IKr or gain of function of INaL on the ventricular action potential result in prolongation of ventricular action potential associated with LQT1, LQT2, and LQT3, respectively (red trace). Simulated action potential with early afterdepolarization events (green trace). C: Simulated normal time course and amplitude of IKr, IKs, and INa currents (black traces). Simulated different mechanisms that can be responsible for LQTS. IKs loss of function associated with LQT1, IKr loss of function associated with LQT2, and gain-of-function INaL associated with LQT3 (currents not drawn to scale). Currents of other ion channels contribution to the action potential (eg, ICa,L, Ito, IK1, and INCx) are not shown for clarity.
properties. hERG 1a are distinguished by the presence of an NH₂ terminal PAS (Per-Arnt-Sim) domain, also referred to as “eag domain,” that is preceded by a shorter PAS-CAP region, whereas hERG 1b has a shorter NH₂ terminal and lacks PAS domain.⁷⁰–⁷²,⁷⁹,⁸⁰ Furthermore, the KCNH channels COOH termini region contains a C-linker and cyclic nucleotide-binding homology domain (CNBHC).⁶⁹,⁸¹ Findings reveal that an inter-subunit interaction between the eag domain and the C-linker CNBHC regulates slow deactivation in the hERG channels at the plasma membrane.⁸²–⁸⁴ The region between the S4 and S5 transmembrane domains (S4–S5 linker) is also implicated in regulating slow deactivation of

---

**Figure 2** Overall topology of KCNQ1, KCNH2, and SCN5A. **A:** KCNQ1 topology. Four KCNQ1 tetramerize to comprise the pore-forming α-subunit; each α-subunit contains 6 transmembrane segments, labeled as S1–S6. SF denotes the selectivity filter. Additionally, Iₖₛ macromolecular complex is illustrated, including β-subunit KCNE1, and associated scaffolding and signaling proteins. **B:** KCNH2, known as the human ether-a-go-go-related gene (hERG). Pore-forming α-subunit transmembrane segments are labeled S1–S6; SF denotes the selectivity filter topology. PAS denotes Per-Arnt-Sim domain, also referred to as “eag domain.” CNBHC denotes cyclic nucleotide-binding homology domain. Additionally, the β-subunit KCNE2 (MiRP1), which associates with KCNH2 α subunits resembling native cardiac I⁶₅ channels, is illustrated. **C:** SCN5A topology of α subunit with auxiliary SCN4B β subunit.
**KCNH channels** 

Under heterologous expression, hERG 1a forms homotetrameric channels, which have robust and slow kinetics of channel closing, whereas hERG 1b forms homotetrameric channels with small currents and faster kinetics of closing than hERG 1a. Fast deactivation of hERG 1b is attributable to the lack of the eag domain, which promotes slow deactivation in hERG 1a. Findings indicate that IKr in human cardiac myocytes and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) are minimally composed of hERG 1a and hERG 1b α subunits. Genetic mutations in both hERG 1a and hERG 1b subunits are associated with LQT2 syndrome, indicating the pathophysiological importance of both isoforms. Mutations in hERG channel that cause LQT2 can reduce the amplitude of IKr by several different mechanisms, which can be defined in 4 classes, including abnormal channel synthesis (transcription/translation) class 1, deficient protein transport or trafficking class 2, abnormal channel gating/kinetics class 3, and disrupted channel permeability or selectivity class 4. All these alterations reduce outward current through hERG channels during repolarization, thus lengthening the cardiac APD, which is reflected on the surface ECG as prolonged QT interval.

In regards to the association of both KCNHa isoforms (hERG 1a-1b), it has also been shown that the β-subunit KCNE2 (MiRP1) associates with KCNHa α subunits resembling native cardiac IKr channel characteristics in their gating, unitary conductance, regulation by potassium, and distinctive biphasic inhibition by the class III antiarrhythmic E-4031. The functional interactions between hERG 1a-1b/KCNE2 ion channel subunits have been investigated, with initial reports suggesting that mutations within KCNE2 β-subunit are implicated as causative of LQT6 syndrome. However, later studies showed that KCNHa rare variants resulting in loss of function do not seem sufficient in isolation to cause LQT6 syndrome but may confer proarhythmic susceptibility when provoked by additional environmental or genetic factors. Moreover, lines of evidence suggest that variants in KCNE2 contribute to a significant fraction of cases of drug-induced LQTS, highlighting the importance of the KCNE2 β-subunit. However, collectively, the importance of KCNHa β-subunit in LQT6 syndrome remains unclear, and further studies are needed to better understand the physiological significance of the role of KCNHa for arrhythmia susceptibility or as a disease-cause gene.

**Clinical aspects and arrhythmic triggers**

After LQT1 syndrome, type 2 LQTS is the second most common LQTS. Diminution in the repolarizing IKr current contributes to lengthening of the QT interval. In patients with LQT2, the majority of cardiac event stimuli are sudden arousal triggers, whereas a lower portion of events are associated with exercise activity. Forty-four percent of cardiac events in LQT2 patients are associated with arousal triggers (like sudden loud noise), 13% with exercise activity, and 43% with nonexercise/nonarousal triggers. Principally, auditory stimuli have been related with triggered cardiac events in LQT2 patients. Sex has also been identified as an important independent contributor to cardiac event risks in LQT2, as adolescent and adult women were shown to have higher risk for cardiac events than the corresponding men in this population. Furthermore, reports show that women with LQTS have a reduced risk for cardiac events during pregnancy, but an increased risk during the 9-month postpartum period, especially among women with LQT2.

In addition to these phenotype-genotype associations, patients with mutations in the pore region of KCNHa gene are at markedly higher risk for arrhythmia-related cardiac events compared with patients with non-pore mutation. Thus, it has been suggested that the risk assessment in LQT2 patients should include trigger-specific recommendations for lifestyle modifications and medical therapy that relate to the age, sex, and location of the mutation of an affected patient.

**LQT3, INa gain of function**

INa, NaV1.5 channel

The gene SCN5A encodes the cardiac voltage-gated pore-forming α-subunit of the Na+ channel (NaV1.5). Two SCN5A splice variants are commonly present in human hearts: 1 comprises 2016 amino acids and contains a glutamine at position 1077 (Q1077) and 1 has only 2015 amino acids because of the absence of this amino acid (Q1077del). The NaV1.5 α-subunit is composed of 4 homologous domains (DI-DIV), each with 6 transmembrane segments (S1–S6). The actual Na+ conducting channel pore is formed by the S5–S6 segments with the pore loop between them. The 3 intracellular linker loops as well as the NH2 and COOH terminus of the channel are cytoplasmic (Figure 2C).

Although the NaV1.5 α-subunit is functional on its own, NaV1.5 forms complexes with auxiliaries’ β subunits that modulate functional NaV1.5 expression. Furthermore, beside β subunits, NaV1.5 channels interact with other proteins that regulate its function or membrane expression.

The NaV1.5 channel permeates inward sodium current (I\textsubscript{Na}), which is the main depolarizing current (phase 0 of the AP) in cardiomyocytes and thus is critical for normal electrical conduction. Upon depolarization, NaV1.5 channel quickly inactivates. While this process happens for the majority of the Na+ channels, there is a small fraction of channels that do not remain inactivated, allowing them to reopen and/or stay open during the repolarization phase of the AP. This current is called “sustained current” or “late current, I\textsubscript{NaL}.” Finally, some channels may reactivate during the repolarizing phase of the AP at a range of potentials where inactivation is not complete and shows overlap with activation, generating the “window current.”
function mutations in SCN5A have been linked to LQT3 syndrome. The most common result in gain of function owing to transient inactivation failure, termed “bursting,” which produces sustained Na+ channel activity over the plateau voltage range of the AP.134 A second is owing to an increase in window current.135,136 The third mechanism is owing to NaV1.5 channels recovering from inactivation faster, resulting in re-opening during AP repolarization.137 Furthermore, mutations in several NaV1.5 channels’ interacting protein partners form part of the rare LQTS susceptibility genes. They include mutations in the gene SCN4B encoding the β4 subunit. Mutations in SCN4B have been linked to LQT10138 and they result in an increase in I_{NaL}. Variants in the CAV3 gene are associated with LQT9 syndrome18,139 and result in enhanced I_{NaL}. Mutations in the SNTA1 gene, which encodes for the scaffold protein α1-syntrophin, have been shown to induce I_{NaL} gain of function and thus join the list of rare LQTS susceptibility genes, as LQT12 syndrome.19

Clinical aspects and arrhythmic triggers

LQT3 syndrome is the third in frequency compared to the 17 forms currently known of congenital LQTS.8,9 However, cardiac events are less frequent in LQT3 when compared with cardiac events in LQT1 and LQT2 patients. Studies have shown that LQT3 patients are less likely to have cardiac events during exercise (13%) and more likely to have events during rest/sleep (29% and 39%).38,59 While the first cardiac event seems to occur later in childhood during or after puberty,140 the first cardiac event is more likely to be lethal; indeed, dying during a cardiac event is higher in LQT3 patients (20%) than LQT1 (4%) and LQT2 (4%).140,141 Moreover, similar lethality from cardiac events was observed between male and female LQT3 patients, at 19% and 18%, respectively.62 Furthermore, mutational-specific risk in patients with 2 relatively common LQT3 mutations has shown that patients with the deletion mutation (ΔKPQ) had a significantly higher risk of cardiac events as compared with patients carrying the missense mutation D1790G,142 which, much like for LQT1 and LQT2, highlights the importance of genotype-specific diagnosis and intervention.

Currently, it is well recognized that patients with LQT3 frequently present with coexistence of associated characteristics, including discrete conduction disturbances, bradycardia, atrial arrhythmias, and Brugada syndrome (BrS). Therefore, in patients with LQT3, overlapping syndromes have been observed.143–146 Importantly, it has also been shown that a single specific SCN5A mutation associated with LQT3 can result in multiple phenotypes in different families or even among members of 1 family.147–149 Moreover, clinical evidence showed that an overlapping syndrome with a phenotype mixed between LQT3 and Purkinje-related premature ventricular contractions can also exist.150 In addition, reports show that there is an association between the LQT3 genotype and risk of early onset of atrial fibrillation.151 Consequently, recognizing the overlapping phenotypes of an SCN5A mutation in a particular patient is of utmost importance not only for designing patient-specific treatment strategies, as drugs used to treat one phenotype may aggravate the other, but also for better risk stratification, as a risk for adverse events may increase when a second phenotype is present.152,153

Other less frequent LQTS-associated mutations

Mutations in 3 more ion channels are also associated with LQTS: CaV1.2, Kir2.1, and Kir3.4. Gain-of-function mutations in the CACNA1C gene encoding the cardiac voltage-gated pore-forming α subunit Ca2+ channel (CaV1.2) lead to LQT8 syndrome (Timothy syndrome).16 Increase in I_{Ca} will delay cardiomyocyte repolarization, resulting in QT interval prolongation.16 Loss-of-function mutations in KCNJ2 and KCNJ5 genes encoding cardiac inward rectifier K+ pore-forming α subunits of Kir2.1 and Kir3.4 channels, which underline I_{K1} and I_{Kach}, are associated with LQT7 (Andersen’s syndrome) and LQT13 syndromes, respectively.17,18 I_{K1} contributes significantly to the repolarizing current during the terminal phase of the cardiac AP and serves as primary conductance controlling the diastolic resting membrane potential in atrial and ventricular myocytes. Reduction in Kir2.1 function would be expected to prolong the cardiac AP and QT interval.21 The I_{Kach} role in ventricular repolarization is clearly relevant, as illustrated by the link between loss-of-function I_{Kach} and LQT13 syndrome.17

Additionally, mutations in adaptor- and signaling-associated proteins are also linked to LQTS. Loss-of-function mutations in ANK2 gene encoding the membrane adaptor proteins ankyrin-B are associated with LQT4 syndrome.24,154 LQT14, LQT15, and LQT16 are caused by variants in CaM encoding genes CALM1, CALM2, and CALM3, respectively.22,23,25,26 Studies have shown that CaM mutations associated with LQTS impair Ca2+ binding affinity and impair modulation of cellular targets, particularly the Ca2+ channel. Specifically, reports have shown that CaM mutants associated with LQTS impair Ca2+ channel-dependent inactivation and induce accentuation in I_{CaL}, and these effects have been demonstrated to prolong the plateau of the cardiac AP.22,26 At this time, the last type of LQTS identified is LQT17, associated with cardiac mutations in the TRDN gene encoding for the triadin protein,27 which is critical to the structure and functional regulation of cardiac muscle calcium release units and excitation-contraction coupling.155 It was speculated that a decrease in I_{CaL} inactivation caused by loss of triadin could lead to prolonged cardiac AP and LQTS phenotype27; however, the precise molecular mechanism of how loss of triadin generates the LQT17 phenotype remains unknown. Furthermore, 2 case report studies suggested that mutations in the Ryr2 gene that encode the ryanodine receptor Ca2+ release channel may play a role in LQTS.156,157 Additionally, findings indicate an association in patients with prolonged QT with deleterious mutations in the SCN10A gene encoding the voltage-gated pore-forming α subunit of NaV1.8.158 Thus, possibly Ryr2 and SCN10A gene mutations will be part of
The diagnosis of LQTS has traditionally relied on the demonstration of prolonged QTc interval as well as the use of a clinical scoring system (Schwartz score) that incorporates surface ECG findings with patient and family histories that include symptoms of syncope, seizures, or aborted cardiac arrest and/or SCD. Although the typical LQTS cases present no diagnostic difficulty, the diagnosis is particularly challenging in asymptomatic LQTS patients, because the Schwartz criteria rely on the presence of symptoms and QT prolongation; consequently, borderline cases are more complex to diagnose. The fact that cardiac events are more often associated with sympathetic stimulation (physical or emotional stress) forms the basis of different provocative tests to uncover concealed LQTS. Therefore, in order to further improve identification of LQTS and to augment the diagnostic sensitivity to further unmask concealed LQTS, different solutions have been proposed: heart rate dependent of QT interval, mental stress test, standing response, sympathetic stimulation, and exercise test. Additionally, the use of provocative drug challenges with epinephrine can be used to facilitate diagnosis.

Moreover, since multiple genes have been implicated in LQTS, clinical genetic testing has now become more commonly performed to identify the causative rare variant. The clinical value of genetic testing has been demonstrated by the evidence that carriers of LQTS mutations lacking QT interval prolongation, who therefore escape clinical diagnosis, have a 10% risk of major cardiac events by age 40 when left untreated. This is where the involvement of a clinical geneticist can play a key role. Indeed, the consequences of missing the LQTS diagnosis in a genetically affected individual or family member with a normal QTc can literally become a question of life or death. In a genotype-positive family, especially with a history of sudden death, it becomes essential for a clinical geneticist to get involved to provide counseling on genetic testing and consequence of the outcome, especially for asymptomatic individuals. This is impactful, since asymptomatic individuals without the knowledge of their genetic predisposition will not receive treatment, will not be aware of the risk of transmitting LQTS to offspring, and will not be informed about avoiding environmental risk factors, such as QT-prolonging drugs, strenuous physical exercise, and extreme psychological stress.

### Table 3  Risk stratification and management in long QT syndrome

| Class | Recommendations |
|-------|-----------------|
| **Class I** | 1. The following lifestyle changes are recommended in all patients with a diagnosis of LQTS: a) Avoidance of QT-prolonging drugs (www.qtdrugs.org) b) Identification and correction of electrolyte abnormalities that may occur during diarrhea, vomiting, metabolic conditions, or imbalanced diets for weight loss.  
  2. Beta-blockers are recommended for patients with diagnosis of LQTS who are: a) Asymptomatic with QTc $\geq 470$ ms and/or b) Symptomatic for syncope or documented ventricular tachycardia/ventricular fibrillation (VT/VF).  
  3. LCSD is recommended for high-risk patients with a diagnosis of LQTS in whom: a) ICD therapy is contraindicated or refused and/or b) Beta-blockers are either not effective in preventing syncope/arrhythmias, not tolerated, not accepted, or contraindicated.  
  4. ICD implantation is recommended for patients with diagnosis of LQT who are survivors of cardiac arrest.  
  5. All QTS patients who wish to engage in competitive sports should be referred to a clinical expert for evaluation of risk. |
| **Class IIa** | 6. Beta-blockers can be useful in patients with a diagnosis of LQTS who are asymptomatic with QTc $\leq 470$ ms.  
  7. ICD implantation can be useful in patients with a diagnosis of LQT who experience recurrent syncopal events while on beta-blocker therapy.  
  8. LCSD can be useful in patients with a diagnosis of LQTS who experience breakthrough events while on therapy with beta-blockers/ICD  
  9. Sodium channel blockers can be useful, as add-on therapy, for LQT3 patients with a QTc $> 500$ ms who shorten their QTc by $> 40$ ms following an acute drug test with one of these compounds. |
| **Class III** | 10. Except under special circumstances, ICD implantation is not indicated in asymptomatic LQTS patients who have not been tried on beta-blocker therapy. |

Adapted from references Priori et al 2013 and Priori et al 2016.  
ICD = implantable cardioverter-defibrillator; LCSD = left cardiac sympathetic denervation; LQTS = long QT syndrome.
LQTS therapeutic interventions

LQTS treatments are targeted at (1) reducing symptomatic arrhythmias, (2) preventing life-threatening arrhythmic events, and (3) reducing SCD risk.\textsuperscript{2,173} Evidence for a major role of the SNS in triggering cardiac events in most LQTS patients provided the rationale for antiadrenergic interventions.\textsuperscript{58,174} In general, congenital LQTS management strategies are similar, independent of the LQTS genotype.\textsuperscript{2,173} The international guidelines advise universal beta-blocker therapy as the drug treatment of choice for LQTS patients who are class I (symptomatic or QTc $\geq$ 470 ms) or class II (asymptomatic with QTc $\leq$ 470 ms).\textsuperscript{2,173} Beta-blockers are indeed very effective, but some LQTS patients continue to have arrhythmic recurrences despite the therapy. Thus, in these patients other management strategies are recommended, such as implantable cardioverter-defibrillator (ICD), left cardiac sympathetic denervation, and sodium channel blockers, which can be useful as an add-on therapy for LQT3 patients with a QTc > 500 ms.\textsuperscript{2,173} Table 3 presents the international ESC and HRS/EHRA/APHRS expert consensus guidelines on management and recommendations for LQTS patients.\textsuperscript{2,173}

An essential component of comprehensive LQTS management is recognizing that clinical expressivity is variable, with some patients having concealed and asymptomatic disease with minimal to no LQTS expressivity, in contrast to those with malignant LQTS. A study has shown that in a highly select group of LQTS patients with clinical profile that includes asymptomatic status, older age at diagnosis, and QTc $< 470$ ms, an observation-only/intentional nontreatment strategy can be considered for very low-risk patients with LQTS after careful clinical evaluation, risk assessment, and institution of prudent precautionary measures such as QT-prolongation drug avoidance. The study showed that such low-risk patients could obtain excellent outcomes without the side effects associated with beta-blockers.\textsuperscript{175} The authors of the study suggested that LQTS patients with this low-risk profile should not receive a prophylactic ICD and that among highly select patients, even guideline-recommended/guideline-supported beta-blocker therapy may be unnecessary; and in such patients, an intentional nontreatment strategy can be considered.\textsuperscript{175}

Moreover, in contrast to LQT1 and LQT2 patients, the use of beta-blocker therapy in LQT3 patients has been more controversial. LQT3 phenotype differs from the more common LQTS. Indeed, LQT3 patient triggers for cardiac events are less likely to be adrenergic and appear to be predominantly bradycardia related.\textsuperscript{58,59} Nevertheless, it was found that beta-blocker therapy was associated with an 83% reduction in cardiac events in LQT3 female patients but the efficacy in male patients could not be determined conclusively because of the low number of events.\textsuperscript{141} Furthermore, a meta-analysis on the efficacy of beta-blockers in LQT1, LQT2, and LQT3 showed that beta-blockers were effective in reducing risks of cardiac events in LQT1 and LQT2 patients but was not able to provide a conclusive statement on the role of beta-blockers on LQT3 owing to data insufficiency.\textsuperscript{176}

However, a recent study aimed at creating an evidence-based risk stratification scheme to personalize the quantification of the arrhythmic risk in patients with LQTS showed that the estimated risk of life-threatening arrhythmia events increases by 15% for every 10 ms increment in the QTc durations for all genotypes, while intergenotype comparison showed that the risk for patients with LQT2 and LQT3 increased by 130% and 157% at any QTc durations vs patients with LQT1. Additionally, the study demonstrated the superiority of the beta-blocker nadolol in significantly reducing arrhythmic risk in all genotypes, compared with no therapy.\textsuperscript{177} Furthermore, the authors of the study provided a novel model to estimate a 5-year risk of life-threatening arrhythmic events in beta-blocker-naive patients with LQTS. This study highlighted the clinical relevance of the model, since it enables discussion with patients for their therapeutic options based on a personalized estimate of the 5-year likelihood for life-threatening arrhythmia events when treatment with beta-blockers is refused or adopted with poor compliance.\textsuperscript{177}

Moreover, the concept of inhibiting INaL or of using different NaV1.5 channel blockers in LQT3 patients has been explored. Lidocaine, mexiletine, and flecaïnine, which have varying selectivity for INaL over peak INa,\textsuperscript{178–180} and ranolazine, a more specific INaL inhibitor,\textsuperscript{181,182} have been tested. However, the enthusiasm to treat LQT3 patients with NaV1.5 channel blockers has been taken very carefully because of the potential adverse effects of this approach owing to potential simultaneous blockade of the peak INa leading to loss-of-function phenotype similar to BrS.\textsuperscript{146,178} In addition, some NaV1.5 channel blockers may facilitate trafficking of mutant NaV1.5 channel, thus exacerbating QT prolongation.\textsuperscript{153} Moreover, owing to nonspecific effects, blockade of 1 of the repolarizing potassium currents may result in further prolongation of the APD. Nevertheless, a clinical benefit was observed in some LQT3 patients owing to pharmacological INaL inhibition.\textsuperscript{178–182}

LQTS genotype-phenotype discordance and single nucleotide polymorphisms

The availability of genetic testing provides and important opportunity to identify and deliver prophylactic treatments to genotype-positive individuals at risk for potential fatal cardiac arrhythmias. However, it has become more and more evident that a mutation in the LQTS-susceptible genes often fails to predict the clinical phenotype, even between members of the same family carrying the same disease-causing mutation. Some genotype-positive patients never develop a clinically relevant disease, some remain asymptomatic (incomplete penetrance), and some show QTc prolongation without cardiac events, whereas others are severely affected and experience serious cardiac events at an early age (variable expressivity).\textsuperscript{2,183} This variation may indicate the presence of significant environmental factors or genetic modifiers, such as common genetic variants of single
nucleotide polymorphisms (SNPs) located in the same or a different gene, which can modulate the functional effect of LQTS mutations and therefore can either exacerbate or mitigate the final LQTS phenotype\(^1\)–\(^{194}\) (Table 4). SNPs can act either independent of or in concert with the LQTS-causing mutation.\(^{195}\) Thus, in addition to the increased interest in genetic investigations of LQTS in general, study focused on identifying the role of SNP over the vastly different clinical course of LQT patients is rising steadily.\(^{190,196–199}\) Moreover, efforts to develop systematic detection of SNP assays has similarly been intensified.\(^{200,201}\)

**novel strategies to study ion channel dysfunction and drug-specific therapies in LQT1, LQT2, and LQT3 syndromes**

The challenges for clinicians reside in the ability to make an early diagnosis, identify LQTS patients at lower vs higher risk of cardiac events, determine the appropriate therapy, and identify LQTS patients displaying incomplete penetrance with different clinical phenotypes (SCD, syncope, asymptomatic). Incomplete penetrance, which is relatively frequent in LQTS, may be caused by more complex genetic models involving multiple genetic and environmental factors affecting the disease development, which represents a challenge for diagnosis and obstacles for the implementation of successful proactive treatments.

**Table 4 Common variants associated with the QTc duration**

| Locus | Gene   | SNP         | MAP | Location    | Function                        | QTc Effect |
|-------|--------|-------------|-----|-------------|---------------------------------|------------|
| 1q    | NOS1AP | rs12143842  | 0.16| Intergenic  | Nitric oxide synthase 1 adaptor protein | ↑          |
|       |        | rs2880058   | 0.26| Intergenic  |                                  |            |
|       |        | rs10494366  | 0.33| Intron      |                                 |            |
|       |        | rs1209454   | 0.11| Intron      |                                 |            |
|       |        | rs16857031  | 0.15| Intron      |                                 |            |
|       |        | rs4657178   | 0.18| Intron      |                                 |            |
| 1q    | ATP1B1 | rs10919071  | 0.11| Intron      | β-subunit Na\(^+\)/K\(^+\)ATPase | ↑          |
| 1p    | RNF207 | rs846111    | 0.26| 3’UTR       | Ring finger protein             | ↑          |
| 3p    | SCN5A  | rs11129795  | 0.34| Intergenic  | α-subunit I\(_{Na}\)           | ↓          |
|       |        | rs12053903  | 0.29| Intron      |                                 |            |
|       |        | rs1805124   | 0.18| Exon (H558R)|                                 | ↑          |
| 6q    | C6orf204| rs12210810  | 0.08| Intergenic  | Phosphorylation                  | ↑          |
| 7q    | KCNH2  | rs2968863   | 0.26| Intergenic  | α-subunit I\(_{Kr}\)          | ↓          |
|       |        | rs4725982   | 0.18| Intergenic  |                                 |            |
|       |        | rs1805123   | 0.24| Exon (K897T)|                                 | ↓          |
| 11p   | KCNQ1  | rs12296050  | 0.23| Intron      | α-subunit I\(_{Ks}\)        | ↑          |
|       |        | rs12576239  | 0.16| Intron      |                                 |            |
|       |        | rs2074238   | 0.08| Intron      |                                 |            |
| 12q   | TBX5   | rs3825214   | 0.22| Intron      | Transcription                   | ↑          |
| 13q   | SULCA2 | rs2478333   | 0.35| Intergenic  | Mitochondrial enzyme            | ↑          |
| 16p   | LITAF  | rs8049607   | 0.49| Intergenic  | Tumor necrosis factor           | ↑          |
| 16q   | CNOT1  | rs37062     | 0.27| Intron      | RNA transcription               | ↓          |
| 17q   | KCNJ2  | rs17779747  | 0.32| Intergenic  | α-subunit I\(_{Ks}\)        | ↑          |
| 17q   | LG3    | rs2074518   | 0.49| Intron      | DNA ligase III                  | ↓          |
| 21q   | KCNE1  | rs1805128   | 0.03| Exon        | β-subunit I\(_{Ks}\)        | ↑          |

MAP = minor allele frequency; SNP = single nucleotide polymorphism.
Adapted from reference Amin et al 2013.
Symbols are as follows:
\(^{1}\)QTc prolongation,
\(^{1}\)QTc shortening.

**Human induced pluripotent stem cell–derived cardiomyocytes**

The human induced pluripotent stem cell–derived cardiomyocyte (hiPSC-CM)-based models have been considered a new paradigm for the development of precision therapeutics that target specific disease mechanisms, personalized drug screening, and exploration of gene therapy through genome editing. In this context, multiple groups including ours have started to investigate and identify factors—either genetic, pharmacological, or environmental—able to modify the clinical course for LQTS patients by acting as modifiers of genes and/or of protein function, expression, or regulation using the hiPSC-CM system.

Our group, in a synergistic manner pairing 3 emergent technologies using hiPSC-CMs, next-generation exome sequencing, and CRISPR/Cas9-mediated genome editing, identified contributors to variable expressivity in an LQT2 family. Our strategy was to first generate iPSC-CM from close symptomatic and asymptomatic relatives, all hERG mutation carriers. We first validated that the genotype-phenotype could be observed by measuring their APs, demonstrating that the phenotype is cell autonomous. Surprisingly, full electrophysiological characterization showed that the affected individuals presented with an increase in calcium currents, which could explain the severe phenotype in these individuals. In parallel, through exome sequencing,
we identified variants explaining the genotype-phenotype discordance in this family, which were then validated through CRISPR/Cas9. Importantly, our findings highlighted the power of combining complementary physiological and genomic analyses to identify genetic modifiers and potential therapeutic targets of monogenic disorders. Furthermore, our study proposed that this strategy can be deployed to unravel myriad confounding pathologies displaying variable expressivity. \(^{202}\) Furthermore, a similar study aimed at determining functional differences between asymptomatic and symptomatic hERG mutation carriers from the same family using iPSC-CM showed that when comparing asymptomatic and symptomatic single hiPSC-CMs, allelic imbalance, potassium current density, and arrhythmogenicity on adrenaline exposure were similar, but a difference in Ca\(^{2+}\) transience was observed. However, the major difference observed by the authors was in hiPSC-CMs at the aggregate level, where increased susceptibility to arrhythmias was observed on aggregate hiPSC-CMs derived from the symptomatic patient. The authors of the study suggested the importance of considering the clinical differences in phenotypes observed in single and aggregate hiPSC-CMs, particularly when conducting preclinical drug toxicity tests. \(^{203}\)

Moreover, patient-independent hiPSC-CM models combined with CRISPR/Cas9-genome editing have also been used to validate the pathogenicity of “variants of unknown significance” (VUS). \(^{204}\) Furthermore, hiPSC-CMs have also been used to identify complex aberrant messenger RNA variants and recapitulated the clinical phenotype of patients with concealed LQT1 syndrome. \(^{205}\) Overall, hiPSC-CMs have been widely used for LQTS modeling and also as a powerful tool for understanding LQTS disease molecular and cellular mechanisms, as well as to determine in a patient-specific manner drug treatment screening. \(^{206–212}\) The use of this hiPSC-CM model has really allowed for major advancement in the study of LQTS in the last few years and will continue to be the ideal platform to study these cardiac genetic diseases, as they allow for the use of cells containing the whole genetic background of the patients.

### High-throughput characterization of LQTS genetic variants

To date, many \(\textit{KCNQ1}, \textit{KCNH2},\) and \(\textit{SCN5A}\) variants have been discovered in LQTS, and with the onset of large population sequencing projects and increase in clinical genetic testing, the number of observed \(\textit{KCNQ1}, \textit{KCNH2},\) and \(\textit{SCN5A}\) variants is rapidly growing, albeit at a much faster rate than the detailed characterization of these variants. Consequently, an important challenge is the identification and characterization of potentially disease-causing \(\textit{KCNQ1}, \textit{KCNH2},\) and \(\textit{SCN5A}\) variants found in LQTS individuals with or without a clinical phenotype. Therefore, to overcome this challenge, researchers have been designing accurate high-throughput strategies that allow to distinguish between VUS that are disease-causing mutations and those that are benign variants. Knowing this information will have enormous implications for the diagnosis, treatment, prognosis, and family counseling of LQTS patients.

The combination of high-efficiency cell electroporation and automated planar patch-clamp is a novel strategy being used to determine in a high-throughput platform the functional consequences of genetic variants. This strategy has been used for the \(\textit{KCNQ1}\) gene, promoting data-driven variant classification of a large number of variants and creating new opportunities for precision medicine. \(^{213}\) Furthermore, in a parallel study the same group of researchers used medium-throughput channel trafficking and stability studies combined with channel functional data to assess \(\textit{KCNQ1}\) variants’ functional and biochemical consequences and to determine their pathogenic mechanisms. The authors of the study discussed the benefits of identifying which \(K_{V}7.1\) loss-of-function mechanism pertains to a given patient. They demonstrated that the appropriate therapeutic approach for a patient with \(\textit{KCNQ1}\) that traffics normally but has defective channel properties is likely to be different from that of a patient with a \(\textit{KCNQ1}\) variant that is prone to mistraffic, but may be functional if it reaches the plasma membrane. \(^{45}\) Similarly, a new method combining high-throughput assessment of single variants through flow cytometry, confocal microscopy and planar patch-clamp electrophysiology was used to detect \(K_{V}11.1\) trafficking-defective channels. The authors of this study generated trafficking scores for \(\textit{KCNH2}\) variants. This assay has the potential to sample all possible amino acids substitution in \(\textit{KCNH2}\) variants in an unbiased manner, providing a database for patients and clinicians to identify the effect of a previously uncharacterized mutation on patient disease propensity. \(^{214}\) Another strategy put forward was to use high-throughput patch-clamp together with surface enzyme-linked immunosorbent assays, which allowed to distinguish between \(\textit{KCNH2}\) benign, dominant-negative, or haploinsufficient variants, helping with \(\textit{KCNH2}\) variant classification. \(^{215}\) Additionally, to test specific treatments for potential variants, pharmacological or temperature strategies were used in combination with high-throughput platforms and showed the enormous potential of these new methods to determine a patient-specific therapy treatment. \(^{216}\)

High-throughput patch-clamp has also been used to determine VUS pathogenicity in \(\textit{SCN5A}\)-related BrS variants. \(^{217}\) However, although the use of high-throughput patch-clamp to accurately measure \(I_{NaL}\) and determine VUS pathogenicity on LQT3 variants represents a bigger challenge, scientists will likely overcome this in the future to measure \(I_{NaL}\) of \(\textit{SCN5A}\) variants on a large scale. Nevertheless, the determination of VUS pathogenicity of \(\textit{SCN5A}\)-related BrS variants is highly relevant to LQT3 patients owing to the sometime coexistence of LQT3 and BrS mixed phenotypes. \(^{143,146}\) Additionally, the accuracy of the high-throughput assay “Deep Mutation Scanning” in \(\textit{SCN5A}\) was validated and identified gain-of-function and loss-of-function pathogenic variants. \(^{215}\) Together, these methodologies will help with the identification and characterization of potentially disease-causing variants, hopefully at a faster pace than variants being identified.
Development of drug-specific therapy

The use of hiPSC-CM-based models for the development of precision therapeutics is a powerful and growing tool. McKeithan and colleagues recently described the use of high-throughput physiological screening for arrhythmic phenotypes in hiPSC-CMs derived from patients with LQT3. Their goal was to facilitate the rapid chemical refinement of mexiletine in order to improve its therapeutic potential and reduce toxicity. The authors of the study identified mexiletine analogues with increased potency and selectivity for inhibiting INaL across a panel of 7 LQT3 variants and were able to suppress arrhythmia activity across multiple genetic and pharmacological hiPSC-CM models of LQT3 with diverse backgrounds. The authors of the study highlighted the potential of the mexiletine analogues as mechanistic probes to improve therapeutic potential and reduce toxicity. Another study was aimed at understanding the molecular basis of LQT3 patients’ variable response to mexiletine. In that study, the authors built a predictive model that can be used for personalized mexiletine treatments based on patients’ genetic variants. They found that mexiletine altered the conformation of domain III voltage sensor domain. Based on this new understanding of the molecular mechanisms for mexiletine blockade of Na,1,5 channels, the authors generated a system-based model on a dataset of 32 patients and were able to successfully predict the response of 7 out of 8 LQT3 patients to mexiletine in a blinded retrospective trial. These findings emphasized that patient-specific response to mexiletine can be predicted, which can certainly improve therapeutic decision making.

An additional challenge with developing drugs that block INaL is that they can act on many other targets, such as other channels (especially hERG channel, IKr) or receptors, resulting in side effects and/or safety concerns. Thus, new drugs have been under development for clinical use. These drugs should have greater potency, efficacy, and selectivity to inhibit INaL without inhibiting IKr and/or prolonging the QT interval. In addition, the drug should not reduce either peak INa or cardiac contractility function. In this context, studies have been focusing on developing next-generation Na+ channel inhibitors that will exhibit increased selectivity for INaL and fulfill all safety concerns.

The current treatment for LQT2 patients is aimed at reducing the incidence of arrhythmia triggers with beta-blockers or terminating the arrhythmia after onset with ICD. However, studies have also considered the alternative strategy of targeting the underlying disease mechanism, which is IKr reduction. Consequently, small molecules have been identified that either enhance Kv11.1 expression (enhancers) or modify Kv11.1 channel function (activators). In this context, different groups assessed shortening of APD in LQT2 hiPSC-CMs using pharmacological tools principally by increasing IKr, but also by testing enhancement of the K+ current IKATP. Moreover, it has been shown that Kv11.1.1 channel activators, which target the primary disease mechanism, provide a possible treatment option for LQT2, with the caveat that there may be a risk of overcorrection that could itself be proarrhythmic.

The novel drug lumacaftor (LUM), a recently FDA-approved cystic fibrosis (CF) protein trafficking chaperone, was used by Mehta and colleagues in LQT2 hiPSC-CMs as a potential novel therapy for LQT2 patients. The first attempt to validate the repurposing strategies for cardiovascular disorders showed that LUM+ivacaftor significantly shortened QTc in the 2 same LQT2 patients with trafficking defect whose hiPSC-CMs were used to study the response to LUM in the study by Mehta and colleagues, confirming the findings. In their conclusion, the authors mentioned that while the findings are encouraging they cautioned that immediate translation into clinical practice, without validation in more patients, would be premature. Furthermore, while LUM is an effective hERG channel trafficking chaperone and may be a therapeutic option for LQT2, caution for its potential use and the importance of understanding the functionality of the LQT2 mutant to be rescued were emphasized by the findings that LUM therapy could also be harmful. Indeed, it was shown that following LUM treatment an alarming increase in the APD was observed in hiPSC-CMs carrying the pG604S hERG mutation. Therefore, these studies highlight the importance of understanding LQT2 patients’ mutant-specific functional characteristics in order to be able to design a patient-specific treatment. Remarkably though, the hiPSC-CM model system provides a very useful system for evaluating rescue as well as side effects of potential therapies for LQTS patients.

Another strategy that was recently explored to rescue ion channel trafficking focused on ubiquitination. This was tested with an engineered deubiquitinate that enables selective ubiquitin chain removal from target proteins to rescue the functional expression of trafficking defective ion channels that underlie either LQT1 or CF. The authors of the study showed that targeted deubiquitination via engineered deubiquitinases provides a powerful protein stabilization method that not only corrects diverse disease caused by impaired ion channel trafficking (LQT1 and CF), but also introduces a new tool for deconstructing the ubiquitin code in situ.

Conclusion

Altogether, hundreds of LQTS mutations are found in KCNQ1, KCNH2, and SCN5A genes. Yet even within 1 gene, the mutations present with different mechanisms and different severity, and even more importantly, variability is also seen for the same mutation among different patients. This variability presents an extraordinary challenge for the physician in determining the best treatment strategy for a specific LQTS patient. However, over the last few years tremendous advances in technologies have allowed characterization of mutations and identification of patient-specific therapies on a large scale. Indeed, the use of hiPSC-CMs, next-generation sequencing, high-throughput patch-clamping, and deep mutation scanning, just to name a few, are all relatively recent
new approaches that have been applied to the study of LQTS, and we are starting to see the benefits by translating our findings from bench to bedside. While promising, at this point these novel strategies to study ion channel function and investigation into drug-specific therapies remain mainly limited to the bench and are not yet fully available for the clinician. But by combining multidisciplinary mechanism-based studies and approaches it will help in our understanding of underlying patient-specific abnormalities, and this information will be crucial to the diagnosis and implementation of successful treatments in LQTS patients, finally getting to precision medicine in LQTS in the near future.

Funding Sources
NIH/NHLBI 1R01HL094450 (ID) and AHA Career Development Award 20CDA35320040 (DPB).

Disclosures
The authors have no conflicts of interest to disclose.

Authorship
All authors attest they meet the current ICMJE criteria for authorship.

References
1. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782–784.
2. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Rev Esp Cardiol (Engl Ed) 2016;69:176.
3. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102:2849–2855.
4. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846–852.
5. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957;54:59–68.
6. Fraser GR, Froggatt P, Murphy T. Genetical aspects of the cardio-auditory syndrome: a disease of sodium channel disruption. Circ Arrhythm Electrophysiol 2008;1:193–201.
7. Schwartz PJ, Moss AJ, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2000;284:2975–2980.
8. Wu G, Ay T, Kim JJ, et al. Alpha-1-syntrophin mutation and the long-QT syndrome: a disease of sodium channel disruption. Circ Arrhythm Electrophysiol 2008;1:193–201.
9. Lu Z, Wu CYC, Jiang YP, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Transl Med 2012;4. 131ra50–131ra50.
10. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005;2:507–517.
11. Landstrom AP, Shah SH. Rare things being common: implications for common genetic variants in rare diseases like long QT syndrome. Circulation 2020;141:418–428.
12. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLIQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178–1185.
13. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005;2:507–517.
14. Wiener R, Haitin Y, Shamgar L, et al. The KCNQ1 (Kv7.1) COOH terminus, a requirement of the CPR complex. Proc Natl Acad Sci U S A 2008;105:9355–9360.
15. Mohler PJ, Splawski I, Napoliitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci 2004;101:9137–9142.
16. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004;119:39–51.
17. Yang Y, Yang Y, Liang B, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010;86:872–880.
18. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006;114:2104–2112.
19. Ueda K, Valdivia C, Medeiros-Domingo A, et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 2008;105:9355–9360.
20. de Villiers CP, van der Merwe L, Croft L, et al. AKAP is a genetic modifier of congenital long-QT syndrome type 1. Circ Cardiovasc Genet 2014;7:599–606.
21. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell 2001;105:511–519.
22. Pipiras DC, Johnson CN, Webster G, et al. Novel calmodulin mutations associated with congenital long QT syndrome affect calcium current in human cardiomyocytes. Heart Rhythm 2016;13:2012–2019.
23. Reed GJ, Boczek NJ, Etheridge SP, Ackerman MJ. CALM3 mutation associated with long QT syndrome. Heart Rhythm 2015;12:419–422.
24. Ohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421:634–639.
25. Chait MA, Koopmann TT, Guyette P, et al. Novel CALM3 mutations in pediatric long QT syndrome patients support a CALM3-specific calmodulinopathy. HeartRhythm Case Rep 2016;2:250–254.
26. Boczek NJ, Gomez-Hurtado N, Ye D, et al. Spectrum and prevalence of CALM1-, CALM2-, and CALM3-encoded calmodulin variants in long QT syndrome and functional characterization of a novel long QT syndrome-associated calmodulin missense variant, E141G. Circ Cardiovasc Genet 2016;9:136–146.
27. Altman HM, Testor DJ, Will ML, et al. Homozygous/compound heterozygous triadin mutations associated with autosomal-recessive long-QT syndrome and pediatric sudden cardiac arrest: elucidation of the triadin knockout syndrome. Circulation 2015;131:2051–2060.
28. Bohnen MS, Peng G, Robey SH, et al. Molecular pathophysiology of congenital long QT syndrome. Physiol Rev 2017;97:89–134.
29. Roden DM, Balser JR, George AL, et al. Anderson ME. Cardiac ion channels. Annu Rev Physiol 2002;64:431–475.
30. Schram G, Pourrier M, Melnik P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 2002;90:939–950.
31. bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198–205.
32. Barhanin J, Lesage F, Guillemaute E, Pimp M, Ladzunski M, Romey GK. LQT1 and LQT2 are distinct currents that form distinct complex of proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:78–80.
33. Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of KvLQT1 and minK (I(k)) proteins to form cardiac I(k) potassium channel. Nature 1996;384:80–83.
34. Jiang M, Wang Y, Tseng GN. Adult ventricular myocytes segregate KCNQ1 and KCNE1 to keep the IKS amplitude in check until when larger IKS is needed. Circ Res Electrophysiol 2017;10:600584.
35. Jost N, Virag L, Bitay M, et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 2005;112:1392–1399.
36. Wiener R, Haitin Y, Shamgar L, et al. The KCNQ1 (Kv7.1) COOH terminus, a multifield scaffold for subunit assembly and protein interaction. J Biol Chem 2008;283:5815–5830.
37. Shamgar L, Mal L, Schmitt N, et al. Calmodulin is essential for cardiac IKS channel gating and assembly: impaired function in long-QT mutations. Circ Res 2006;98:1055–1063.
38. Bendahhou S, Marionneau C, Haurou K, et al. In vitro molecular interactions and distribution of KCNQ1 family with KCNQ1 in the human heart. Cardiovasc Res 2005;67:529–538.
39. Lundquist AL, Manderfield LJ, Vanoye CG, et al. Expression of multiple KCNQ genes in human heart may enable variable modulation of IKs. J Mol Cell Cardiol 2005;38:277–287.
40. Tinel N, Diochot S, Borsotto M, Ladzunski M, Barhanin J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. EMBO J 2000;19:6326–6330.
41. Melman YF, Domenech A, de la Luna S, McDonald TV. Structural determinants of KvLQT1 control by the KCNQ1 family of proteins. J Biol Chem 2001;276:6439–6444.
42. Chen J, Zheng R, Melman YF, McDonald TV. Functional interactions between KCNE1 C-terminus and the KCNQ1 channel. PLoS One 2009;4:e5143.

43. Loussouarn G, Park KH, Bellocq C, Baro I, Charpentier F, Escande D. Phosphatidylinositol-4,5-bisphosphate, PIP2, controls KCNQ1/KCNE1 voltage-gated potassium channels: a functional homology between voltage-gated and inward rectifier K+ channels. J Biol Chem 2003;278:5412–5421.

44. Chen J, Liu Z, Creagh J, Zheng R, McDonald TV. Physical and functional interaction sites in cytoplasmic domains of KCNQ1 and KCNE1 channel subunits. Am J Physiol Heart Circ Physiol 2020;318:H1212–H1222.

45. Huang H, Kuenze G, Smith JA, et al. Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. Sci Adv 2018;4:eaa6236.

46. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the lminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997;17:338–340.

47. Schulze-Bahrm E, Wang Q, Wedekind H, et al. KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet 1997;17:267–268.

48. Li Y, Zaydman MA, Wu D, et al. KCNE1 enhances phosphatidylinositol 4,5-bisphosphate (PIP2) sensitivity of IKs to modulate channel activity. Proc Natl Acad Sci U S A 2007;104:20990–20995.

49. Park KH, Piron J, Dahimene S, et al. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate (PIP2) signaling of IKs to modulate channel activity. Proc Natl Acad Sci U S A 2011;108:9095–9100.

50. Park KH, Piron J, Dahimene S, et al. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome. Circ Res 2005;96:730–739.

51. Marx SO, Kurokawa J, Kurokawa J, et al. Requirement of a macromolecular channel macromolecular complex includes the phosphodiesterase PDE4D3. J Cardiovasc Pharmacol 2011;57:439–444.

52. Efendiev R, Dessauer CW. A kinase-anchoring proteins and adenylyl cyclase in cardiovascular physiology and pathology. J Cardiovasc Pharmacol 2011;58:339–344.

53. Terrenoere C, Houslay MD, Baille GS, Kass RS. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem 2009;284:9140–9146.

54. Li Y, Chen L, Kass RS, Dessauer CW. The A-kinase anchoring protein Yotia facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel. J Biol Chem 2012;287:29815–29824.

55. Chen L, Manquardi ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci U S A 2007;104:20990–20995.

56. Bottiglieri D, Monaco I, Santacroce R, et al. Novel AKAP9 mutation and long QT syndrome in a patient with torsades de pointes. J Interv Card Electrophysiol 2019;56:171–172.

57. Sanguinetti MC. Long QT syndrome: ionic basis and arrhythmia mechanism in long QT syndrome type 1. J Cardiovasc Electrophysiol 2000;11:710–712.

58. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in long QT syndrome. J Am Coll Cardiol 2004;44:117–125.

59. Park KH, Piron J, Dahimene S, et al. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate (PIP2) signaling of IKs to modulate channel activity. Proc Natl Acad Sci U S A 2007;104:20990–20995.

60. Goldenberg I, Thottathil P, Lopes CM, et al. Trigger-specific potential differences in congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004;44:117–125.

61. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, Mackinnon R. Crystal structure of the human ether-a-go-go-related gene (hERG) potassium channel. Cell 1995;81:299–307.

62. Brelidze TI, Gianulis EC, DiMaio F, Trudeau MC, Zagotta WN. Structure of the human minK channel. EMBO J 2003;22:5412–5421.

63. McNally BA, Pendon ZD, Trudeau MC, hERG1a and hERG1b potassium channel subunits directly interact and preferentially form heteromeric channels. J Biol Chem 2017;292:21548–21557.

64. Sale H, Wang J, O’Hara TJ, et al. Physiological properties of hERG 1a/b and hERG1b potassium channels. J Biol Chem 2000;275:25485–25500.

65. Gustina AS, Trudeau MC. The eukaryotic PAS domain. Cell 1998;95:649–655.

66. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, Mackinnon R. Crystal structure and functional analysis of the hERG potassium channel N terminus: a eukaryotic PAS domain. Cell 1998;95:649–655.

67. Guy HR, Durell SR, Warmke J, Drysdale R, Ganetzky B. Similarities in amino acid sequences of Drosophila e and cyclic nucleotide-gated channels. Science 1991;254:730.

68. Phartiyal P, Sale H, Jones EM, Robertson GA. Endoplasmic reticulum retention and rescue by heteromeric assembly regulate human ERG 1a/b surface channel composition. J Biol Chem 2008;283:3702–3707.
146. Priori SG, Napolitano C, Schwartz PJ, Blosse R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000;102:945–947.

147. Zhang Y, Wang J, Chang S, et al. The SCN5A mutation A1807V is associated with electrophysiographic features of LQT3. Pediatr Cardiol 2014;35:295–300.

148. Veitmann C, Barajas-Martinez H, Wolpert C, et al. Further insights in the most common SCN5A mutation causing overlapping phenotype of long QT syndrome, Brugada syndrome, and conduction defect. J Am Heart Assoc 2016;5.

149. Shi R, Zhang Y, Yang C, et al. The cardiac sodium channel mutation delQKP 1507-1509 is associated with the expanding phenotypic spectrum of LQT3, conduction disorder, dilated cardiomyopathy, and high incidence of youth sudden death. Europace 2008;10:1329–1335.

150. Barak W, Giudicessi JR, Asirvatham SJ, Ackerman MJ. Purkinje system hyperexcitability and ventricular arrhythmia risk in type 3 long QT syndrome. Heart Rhythm 2020;17:1768–1776.

151. Platonov PG, McNitt S, Polonsky B, et al. Prolonged QTc interval in LQTS carriers without clinical indication for genetic testing. J Cardiovasc Electrophysiol 2020;43:1521.

152. Ruan Y, Denegri M, Liu N, et al. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circ Res 2010;106:1374–1383.

153. Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995;57:1114–1122.

154. Chopra N, Yang T, Asghar P, et al. Ablation of triad causes loss of cardiac Cav1.2 release unit required for excitation–contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci U S A 2009;106:7636–7641.

155. Taniguchi Y, Miyazaki A, Sakaguchi H, et al. Prominent QTc prolongation in a patient with rare variant in the cardiac ryanodine receptor gene. Heart Vessels 2017;32:229–233.

156. Kaufman ES, Gorodeski EZ, Dettmer MM, Dikshteyn M. Use of autonomic maneuvers to probe phenotype/genotype discordance in congenital long QT syndrome. Pacing Clin Electrophysiol 2020;43:1521.

157. Noda T, Takaki H, Kurita T, et al. Gene-specific test to unmask long QT syndrome. Europace 2018;20:514–520.

158. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome: clinical impact. Circulation 1999;99:529–533.

159. Amin AS. SCN5A override syndromes-this episode: long QT syndrome type 3 meets multiform ectopic Purkinje-related premature contractions. Heart Rhythm 2020;17:1777–1778.

160. Taniguchi Y, Kusumoto F, Krakoff K, et al. Effectiveness of beta-blocker therapy in congenital long QT syndrome. Circulation 2000;101:616–623.

161. Macntryte CJ, Rohtagi RK, Sugrue AM, Bos JM, Ackerman MJ. Intentional nontherapy in long QT syndrome. Heart Rhythm 2020;17:1147–1150.

162. Amin AS, Macarana R, Vacanti G, et al. Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol 2018;71:1663–1671.

163. Shinlapawittayatorn K, Du XX, Liu H, Ficker E, Kaufman ES, Deschenes I. A novel strategy using cardiac crosstalk to prevent tachyarrhythmias in patients with sustained inward sodimu current due to type-3 long QT syndrome. J Cardiovasc Electrophysiol 2008;19:1289–1293.

164. Petska E, Zhang Y, Kusumoto F, et al. Long QT syndrome: a transatlantic clinical phenotype. Circ Arrhythm Electrophysiol 2011;4:29–39.

165. Platonov PG, McNitt S, Polonsky B, et al. Prolonged QT. Clin Genet 2018;93:741–748.

166. Crotti L, Lahtinen AM, Spazzolini C, et al. Genetic modifiers of the long QT syndrome type III: experimental and long-term clinical data. Circ Arrhythm Electrophysiol 2016;9:e004370.

167. Kaufman ES, Gorodeski EZ, Deschenes I, Ackerman MJ. Atrial fibrillation in patients with LQTS who meet multifocal ectopic Purkinje-related premature contractions. Heart Rhythm 2020;17:1777–1778.

168. Mazzanti A, Maragara R, Faraghi A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol 2016;67:1053–1058.

169. Blich M, Khoury A, Malembrato M, LoPerfis L, Boulous M. Specific therapy based on the genotype in a malignant form of long QT, carrying the V411M mutation. Int Heart J 2019;60:979–982.

170. Erturk E, de Feo L, Gennari L, et al. Diagnostic usefulness of QTc interval in identifying individuals at risk for sudden cardiac death. Eur J Clin Pharmacol 2013;69:947–953.

171. Shinlapawittayatorn K, Du XX, Liu H, Ficker E, Kaufman ES, Deschenes I. A novel strategy using cardiac crosstalk to prevent tachyarrhythmias in patients with sustained inward sodimu current due to type-3 long QT syndrome. J Cardiovasc Electrophysiol 2008;19:1289–1293.

172. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome: clinical impact. Circulation 1999;99:529–533.

173. Azziz PF, Wieand TS, Ganley J, Henderson J, McBride M, Shah MJ. Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing? Ann Noninvasive Electrocardiol 2013;18:288–293.

174. Shinlapawittayatorn K, Du XX, Liu H, Ficker E, Kaufman ES, Deschenes I. A novel strategy using cardiac crosstalk to prevent tachyarrhythmias in patients with sustained inward sodimu current due to type-3 long QT syndrome. J Cardiovasc Electrophysiol 2008;19:1289–1293.

175. Amin AS, Macarana R, Faraghi A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol 2016;67:1053–1058.
212. Mesquita FCP, Arantes PC, Kasai-Brunswick TH, et al. R534C mutation in LQT2 syndrome from asymptomatic and symptomatic mutation carriers reproduces clinical differences in aggregates but not in single cells. Cells 2020; 9:1153.

213. Chavali NV, Kryshtal DO, Parikh SS, et al. Patient-independent human induced pluripotent stem cell model: a new tool for rapid determination of genetic variant pathogenicity in long QT syndrome. Heart Rhythm 2019;16:1686–1695.

214. Wurinyah T, Maizyama T, Sasaki K, et al. Complex aberrant splicing in the induced pluripotency stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Asp mutation. Heart Rhythm 2018; 15:1566–1574.

215. Yazawa M, Huehe B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230–234.

216. Izhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225–229.

217. Portero V, Casini S, Hoekstra M, et al. Anti-arrhythmic potential of the late sodium current in iPSC-derived cardiomyocytes from a patient with long QT syndrome carrying KSNC5A-1795insD mutation. Heart Rhythm 2018; 15:277–286.

218. Rajamani S, Liu G, El-Bizri N, et al. The novel late Na(+) channel with improved efficacy and potency relative to ranolazine. Bioorg Med Chem Lett 2016;26:3202–3211.

219. Zablocki JA, Elzein E, Li X, et al. Discovery of dihydrobenzoxazepinone (GS-462808, a late sodium current inhibitor (late INa)), a phase II agent with demonstrated preclinical anti-ischemic and antiarrhythmic properties. J Med Chem 2016;59:9005–9017.

220. Kanner SA, Shuja Z, Choudhury P, Jain A, Colecraft HM. Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies. Nat Methods 2018;15:1445–1455.

221. Schwartz PJ, Gnecchi M, Dagradi F, et al. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. Eur Heart J 2018;39:1446–1455.

222. Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB. Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules. Acta Pharmocol Sin 2011;32:781–788.

223. Vanoye CG, Desai RR, Fabre KL, et al. High-throughput functional evaluation of KCNQ1 decrypts variants of unknown significance. Circ Genom Precis Med 2018;11:e002345.

224. Kozek KA, Glazer AM, Ng CA, et al. High-throughput screening of trafficking-deficient variants in the cardiac potassium channel KV11.1. Heart Rhythm 2020; 17(12):2180–2189.

225. Ng CA, Perry MD, Liang W, et al. High-throughput phenotyping of heterometric human ether-a-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants. Heart Rhythm 2020;17:492–500.

226. Kanner SA, Jain A, Colecrt HM. Development of a high-throughput flow cytometry assay to monitor defective trafficking and rescue of long QT2 mutant hERG channels. Front Physiol 2018;9:397.